Metastatic ovarian cancer and gastrointestinal stromal tumor on the grounds of neurofibromatosis. A case report and review of the literature

Neurofibromatosis type 1 (NF1) is an inherited neurocutaneous syndrome. NF1 patients are at increased risk for both benign and malignant tumors. The authors present the case of a female patient with a medical history of NF1, with an impressive succession of tumors, namely metastatic ovarian cancer and, 20 years later, a gastrointestinal stromal tumor (GIST) of the jejunum. The metastatic ovarian Mullerian adenosarcoma was successfully treated with total abdominal hysterectomy with bilateral salpingo-oophorectomy, radiotherapy, chemotherapy, as well as Gamma Knife radiosurgery of the metastasis in the thalamus. The jejunal GIST was surgically removed. The exploration of molecular pathways that underlie the association between NF1, GISTs, and ovarian cancer may provide valuable insight into the pathogenesis of such cases and assessment of targeted therapies.

Neurofibromatosis type 1; Ovarian cancer; Gastrointestinal stromal tumor; Metastasis.

[1] Reynolds R.M., Browning G.G., Nawroz I., Campbell I.W.: “Von Recklinghausen’s neurofibromatosis: neurofibromatosis type 1”. Lancet, 2003, 361, 1552.

[2] Rad E., Tee A.R.: “Neurofibromatosis type 1: fundamental insights into cell signalling and cancer”. Semin. Cell. Dev. Biol., 2016, 52, 39

[3] Patil S., Chamberlain R.S.: “Neoplasms associated with germline and somatic NF1 gene mutations”. Oncologist, 2012, 17, 101.

[4] Anderson J.L., Gutmann D.H.: “Neurofibromatosis type 1”. Handb. Clin. Neurol., 2015, 132, 75-86.

[5] Rasmussen S.A., Friedman J.M.: “NF1 gene and neurofibromatosis 1”. Am. J. Epidemiol., 2000, 151, 33.

[6] Abramowicz A., Gos M.: “Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease”. Dev. Period. Med., 2014, 18, 297.

[7] Hernandez-Martin A., Duat-Rodriguez A.: “An Update on Neurofibromatosis Type 1: Not Just Cafe-au-Lait Spots and Freckling. Part II. Other Skin Manifestations Characteristic of NF1. NF1 and Cancer”. Actas Dermosifiliogr 2016, 107, 465. [Article in English, Spanish]

[8] Miettinen M., Lasota J.: “Histopathology of gastrointestinal stromal tumor”. J. Surg. Oncol., 2011, 104, 865.

[9] Gheorghe M., Predescu D., Iosif C., Ardeleanu C., Bacanu F., Constantinoiu S.: “Clinical and therapeutic considerations of GIST”. J. Med. Life, 2014, 7, 139.

[10] Maertens O., Prenen H., Debiec-Rychter M., Wozniak A., Sciot R., Pauwels P., et al.: “Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients”. Hum. Mol. Genet., 2006, 15, 1015.

[11] Mussi C., Schildhaus H.U., Gronchi A., Wardelmann E., Hohenberger P.: “Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1”. Clin. Cancer Res., 2008, 14, 4550.

[12] Protopapas A., Sotiropoulou M., Haidopoulos D., Athanasiou S., Loutradis D., Antsaklis A.: “Ovarian neurofibroma: a rare visceral occurrence of type 1 neurofibromatosis and an unusual cause of chronic pelvic pain”. J. Minim. Invasive Gynecol., 2011, 18, 520.

[13] Hegg C.A., Flint A.: “Neurofibroma of the ovary”. Gynecol. Oncol., 1990, 37, 437.

[14] Tato B.P., Saez A.C., Recuero J.L., Dorado M.M., Fernandez P.R., de Paz F.S.: “Neurofibromatosis of atypical presentation”. J. Eur. Acad. Dermatol. Venereol., 2005, 19, 608.

[15] Friedlander M.L., Covens A., Glasspool R.M., Hilpert F., Kristensen G., Kwon S., et al.: “Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract”. Int. J. Gynecol. Cancer, 2014, 24, S78.

[16] Van Mieghem T, Abeler VM, Moerman P, Verbist L, Vergote I, Amant F. CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma. Gynecol Oncol 2005; 99: 493-496.

[17] Howitt BE, Sholl LM, Dal Cin P, Jia Y, Yuan L, MacConaill L et al. Targeted genomic analysis of Mullerian adenosarcoma. J Pathol 2015; 235: 37-49.

[18] Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 2015; 15: 290-301.

[19] Bakker AC, La Rosa S, Sherman LS, Knight P, Lee H, Pancza P, Nievo M.: “Neurofibromatosis as a gateway to better treatment for a variety of malignancies”. Prog. Neurobiol., 2016 Feb 5. pii: S0301- 0082(15)30049-6. doi: 10.1016/j.pneurobio.2016.01.004. [Epub ahead of print]

[20] Chang T., Krisman K., Theobald E.H., Xu J., Akutagawa J., Lauchle J.O., et al.: “Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice”. J. Clin. Invest., 2013, 123, 335.

[21] Robertson K.A., Nalepa G., Yang F.C., Bowers D.C., Ho C.Y., Hutchins G.D., et al.: “Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial”. Lancet. Oncol., 2012, 13, 1218.